Chimeric Mouse Model with
Highly Humanized Liver
Highly Humanized Liver
KMT Hepatech, Inc. is a part of PhoenixBio group since December 1, 2017
KMT Hepatech is a production facility of PhoenixBio Group products (PXB-mouse® and PXB-cells®) in North America.
PhoenixBio Group is utilizing its proprietary platform technology of small animal model of chimeric mouse with highly humanized liver, the PXB-mouse®.
The PXB-mouse® and PXB-cells® are your essential tools for therapeutics and vaccine development.
Commercial scale production of high quality chimeric mice
Always available for shipment
Stable engraftment for entire lifespan
Long-term applications – over 30 days in study
On-demand supply with consistent donor for in vitro reproducibility
Compatible with your preferred format including 3D
News and Events
Fresh human hepatocytes for your research
PXB-cells® applications PXB-cells® are fresh human hepatocytes isolated from the PXB-mouse®. We offer consistent delivery on your schedule and from the same donor source. PXB-cells® are useful in many application…
International NASH Day 2020
International NASH Day – June 12 – is aimed to increase public awareness about non-alcoholic steatohepatitis (NASH). NASH is characterized by the presence of an abnormal accumulation of fat in…
Glucuronidation and PK of anti-cancer drug candidate
PXB-mouse® was used to assess glucuronide formation and pharmacokinetics in human hepatocytes in vivo, as published by Phenex Pharmaceuticals AG team in ACS Medicinal Chemistry Letters “Discovery of Hydroxyamidine Based…
Digital Communication in Science and Business – Is It “New Normal”?
During last two months many of us saw their colleagues only via such applications as Zoom, WebEx, Google Hangouts and other video conferencing systems. With conferences and workshops going virtual,…
Species differences in liver accumulation and metabolism
Species differences in liver accumulation and metabolism of nucleotide prodrug are discussed in the April 2020 publication by Gilead team. The difficulty in projecting human dose based on preclinical data…
COVID-19 Update from PhoenixBio Group
PhoenixBio’s Response to COVID19 Dear Valued Customers, Collaborators and Partners, We are writing this letter to ensure you that the PhoenixBio Group continues to operate at full capacity and is…